76 related articles for article (PubMed ID: 20032410)
21. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
[TBL] [Abstract][Full Text] [Related]
22. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
23. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
Almeras C; Zerbib M; Eschwege F; Debré B
Prog Urol; 2002 Apr; 12(2):219-25. PubMed ID: 12108335
[TBL] [Abstract][Full Text] [Related]
24. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
25. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
27. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
[TBL] [Abstract][Full Text] [Related]
28. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
29. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
30. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
31. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
33. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
34. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
35. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
King CR; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668
[TBL] [Abstract][Full Text] [Related]
36. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
37. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
Rosser CJ; Levy LB; Kuban DA; Chichakli R; Pollack A; Lee A; Pisters LL
J Urol; 2003 Jun; 169(6):2160-5. PubMed ID: 12771739
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy for regionally localized hormone refractory prostate cancer.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):907-12. PubMed ID: 7591901
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients.
Cetin IA; Akay SU; Sengoz M
BMC Urol; 2022 Nov; 22(1):182. PubMed ID: 36376849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]